Prognostic risk score model and bioinformatics analysis of antioxidant-associated lncRNAs in gastric cancer
10.3969/j.issn.1009-9905.2024.02.007
- VernacularTitle:胃癌抗氧化相关lncRNAs预后风险评分模型的构建及生信分析
- Author:
Xiao-Xin ZHANG
1
;
Zi-Peng XU
;
Yan-Sheng LU
;
Jie CHENG
;
Zheng-Hai ZHU
Author Information
1. 无锡市锡山人民医院 普外科(江苏 无锡 214105)
- Keywords:
Gastric neoplasms;
Antioxidant;
Long non-coding RNA;
Prognosis;
Bioinformatics
- From:
Chinese Journal of Current Advances in General Surgery
2024;27(2):122-128
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the value of antioxidant-associated long non-coding RNAs(lncRNAs)risk score model in prognosis and the association with immune microenvironment of the gastric cancer patients.Methods:Gastric cancer transcriptome data and clinical information were downloaded from TCGA database.Antioxidant-associated lncRNAs were obtained by co-ex-pression analysis of lncRNAs and antioxidant genes.Risk score was constructed using univariate cox regression analysis and lasso regression analysis.Log-Rank test was used to compare the survival differences between two groups.Receiver operating characteristic curve(ROC)was used to assess the specificity and sensitivity of the prognostic risk score model.Nomogram was constructed com-bining risk score and clinical parameters.Immune cell infiltration was assessed by TIMER 2.0.Im-munotherapy sensitivity of each sample was analyzed at TIDE website.Results:A risk score in-cluding 12 IncRNAs was constructed by univariate cox regression analysis and lasso regression anal-ysis.The risk score was an independent factor influencing patient prognosis[HR=5.406(3.131～9.335),P＜0.001].Risk score was positively correlated with multiple suppressive immune cells infil-tration(M2 macrophage,tumor-associated fibroblast).Meanwhile,multiple aberrant expression of immune checkpoint genes and higher TIDE score were found in high-risk group,suggesting that high-risk groups may be more sensitive to immunotherapy.Conclusion:The antioxidant-associ-ated IncRNAs risk score is a good prognostic predictor and can act as a reference in individualized immunotherapy for gastric cancer patients.
